Categories
Publications

Ocado cuts sick pay for unvaccinated staff – Grocery Gazette

Ocado has announced it is cutting sick pay for unvaccinated staff who must self-isolate due to exposure to Covid-19.

According to the BBC, the online grocer will continue to offer full sick pay if unvaccinated workers test positive for the virus but will reduce sick pay for exposure related isolation.

http://archive.today/2022.01.17-172326/https://www.grocerygazette.co.uk/2022/01/14/ocado-cuts-sick-pay-for-unvaccinated-staff/

Categories
Publications

Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts – Nature Communications

Cross-reactive immune responses to SARS-CoV-2 have been observed in pre-pandemic cohorts and proposed to contribute to host protection. Here we assess 52 COVID-19 household contacts to capture immune responses at the earliest timepoints after SARS-CoV-2 exposure. Using a dual cytokine FLISpot assay on peripheral blood mononuclear cells, we enumerate the frequency of T cells specific for spike, nucleocapsid, membrane, envelope and ORF1 SARS-CoV-2 epitopes that cross-react with human endemic coronaviruses. We observe higher frequencies of cross-reactive (p = 0.0139), and nucleocapsid-specific (p = 0.0355) IL-2-secreting memory T cells in contacts who remained PCR-negative despite exposure (n = 26), when compared with those who convert to PCR-positive (n = 26); no significant difference in the frequency of responses to spike is observed, hinting at a limited protective function of spike-cross-reactive T cells. Our results are thus consistent with pre-existing non-spike cross-reactive memory T cells protecting SARS-CoV-2-naïve contacts from infection, thereby supporting the inclusion of non-spike antigens in second-generation vaccines.

http://archive.today/2022.01.10-120437/https://www.nature.com/articles/s41467-021-27674-x

Categories
Publications

Deaths from COVID-19 with no other underlying causes – Office for National Statistics

You asked
Please can you advise on deaths purely from covid with no other underlying causes.

We said
Thank you for your request.

…Please see below for death registrations for 2020 and 2021 (provisional) that were due to COVID-19 and were recorded without any pre-existing conditions, England and Wales.

2020: 9400 (0-64: 1549 / 65 and over: 7851)

2021 Q1: 6483 (0-64: 1560/ 65 and over: 4923)

2021 Q2: 346 (0-64: 153/ 65 and over: 193)

2021 Q3: 1142 (0-64: 512/ 65 and over: 630)

https://www.ons.gov.uk/aboutus/transparencyandgovernance/freedomofinformationfoi/deathsfromcovid19withnootherunderlyingcauses

Categories
Publications

The Supply of ITU Medicines and End of Life Care Medicines for Covid-19 Preparedness – GOV.UK

The Authority seeks to top up the Stockpile holdings of Midazolam 50mg/10ml vial (EOL) and Noradrenaline 8mg/8ml for infs Amp (ITU) medicines in preparations for further waves of Covid 19 in Winter 2021/ Spring 2022.

https://web.archive.org/web/20211211101310/https://www.contractsfinder.service.gov.uk/Notice/6e5930bd-6c46-4839-8dea-87aa770d3bf3

Categories
Publications

Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals – bioRxiv

These data suggest that virtually all individuals with existing anti-SARS-CoV-2 CD8+ T-cell responses should recognize the Omicron VOC, and that SARS-CoV-2 has not evolved extensive T-cell escape mutations at this time.

http://archive.today/2021.12.12-062920/https://www.biorxiv.org/content/10.1101/2021.12.06.471446v1

Categories
Publications

Latest statistics on England mortality data suggest systematic mis-categorisation of vaccine status and uncertain effectiveness of Covid-19 vaccination – ResearchGate

However, despite this apparent evidence to support vaccine effectiveness – at least for the older age groups – on closer inspection of this data, this conclusion is cast into doubt. That is because we have shown a range of fundamental inconsistencies and flaws in the data. Specifically:
• In each group the non-Covid mortality rates in the three different categories of vaccinated people fluctuate in a wild, but consistent way, far removed from the expected historical mortality rates.
• Whereas the non-Covid mortality rate for unvaccinated should be consistent with historical mortality rates (and if, anything slightly lower than the vaccinated non-Covid mortality rate) it is not only higher than the vaccinated mortality rate, but it is far higher than the historical mortality rate.
• In previous years each of the 60-69, 70-79 and 80+ groups have mortality peaks at the same time during the year (including 2020 when all suffered the April Covid peak at the same time). Yet in 2021 each age group has non-Covid mortality peaks for the unvaccinated at a different time, namely the time that vaccination rollout programmes for those cohorts reach a peak.
• The peaks in the Covid mortality data for the unvaccinated are inconsistent with the actual Covid wave.

Whatever the explanations for the observed data, it is clear that it is both unreliable and misleading. We considered the socio-demographic and behavioural differences between vaccinated and unvaccinated that have been proposed as possible explanations for the data anomalies, but found no evidence supports any of these explanations. By Occam’s razor we believe the most likely explanations are:
• Systematic miscategorisation of deaths between the different groups of unvaccinated and vaccinated.
• Delayed or non-reporting of vaccinations.
• Systematic underestimation of the proportion of unvaccinated.
• Incorrect population selection for Covid deaths.

http://archive.today/2021.12.04-015020/https://www.researchgate.net/publication/356756711_Latest_statistics_on_England_mortality_data_suggest_systematic_mis-categorisation_of_vaccine_status_and_uncertain_effectiveness_of_Covid-19_vaccination

Categories
Publications

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel – The New England Journal of Medicine

Background
Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) by May 31, 2021. After early reports of myocarditis during adverse events monitoring, the Israeli Ministry of Health initiated active surveillance.

Conclusions
The incidence of myocarditis, although low, increased after the receipt of the BNT162b2 vaccine, particularly after the second dose among young male recipients. The clinical presentation of myocarditis after vaccination was usually mild.

http://archive.today/2021.10.10-032642/https://www.nejm.org/doi/full/10.1056/NEJMoa2109730

Categories
Publications

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome – Science Advances

Vaccines derived from chimpanzee adenovirus Y25 (ChAdOx1), human adenovirus type 26 (HAdV-D26), and human adenovirus type 5 (HAdV-C5) are critical in combatting the severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic. As part of the largest vaccination campaign in history, ultrarare side effects not seen in phase 3 trials, including thrombosis with thrombocytopenia syndrome (TTS), a rare condition resembling heparin-induced thrombocytopenia (HIT), have been observed. This study demonstrates that all three adenoviruses deployed as vaccination vectors versus SARS-CoV-2 bind to platelet factor 4 (PF4), a protein implicated in the pathogenesis of HIT. We have determined the structure of the ChAdOx1 viral vector and used it in state-of-the-art computational simulations to demonstrate an electrostatic interaction mechanism with PF4, which was confirmed experimentally by surface plasmon resonance. These data confirm that PF4 is capable of forming stable complexes with clinically relevant adenoviruses, an important step in unraveling the mechanisms underlying TTS.

http://archive.today/2021.12.02-125456/https://www.science.org/doi/10.1126/sciadv.abl8213

Categories
Publications

The epidemiological relevance of the COVID-19-vaccinated population is increasing – Science Direct

High COVID-19 vaccination rates were expected to reduce transmission of SARS-CoV-2 in populations by reducing the number of possible sources for transmission and thereby to reduce the burden of COVID-19 disease. Recent data, however, indicate that the epidemiological relevance of COVID-19 vaccinated individuals is increasing. In the UK it was described that secondary attack rates among household contacts exposed to fully vaccinated index cases was similar to household contacts exposed to unvaccinated index cases (25% for vaccinated vs 23% for unvaccinated). 12 of 31 infections in fully vaccinated household contacts (39%) arose from fully vaccinated epidemiologically linked index cases. Peak viral load did not differ by vaccination status or variant type.

http://archive.today/2021.11.24-055915/https://www.sciencedirect.com/science/article/pii/S2666776221002581

Categories
Publications

The epidemiological relevance of the COVID-19-vaccinated population is increasing – The Lancet

High COVID-19 vaccination rates were expected to reduce transmission of SARS-CoV-2 in populations by reducing the number of possible sources for transmission and thereby to reduce the burden of COVID-19 disease. Recent data, however, indicate that the epidemiological relevance of COVID-19 vaccinated individuals is increasing.

…The US Centres for Disease Control and Prevention (CDC) identifies four of the top five counties with the highest percentage of fully vaccinated population (99.9–84.3%) as “high” transmission counties.

http://archive.today/2022.01.04-173519/https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00258-1/fulltext

Categories
Publications

Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021 – medRxiv

Conclusions As this field continues to develop, clinicians and public health practitioners should consider vaccinated persons who become infected with SARS-CoV-2 to be no less infectious than unvaccinated persons. These findings are critically important, especially in congregate settings where viral transmission can lead to large outbreaks.

http://archive.today/2021.11.25-185840/https://www.medrxiv.org/content/10.1101/2021.11.12.21265796v1

Categories
Publications Videos

Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning – Circulation Journal, American Heart Association

We conclude that the mRNA vacs dramatically increase inflammation on the endothelium and T cell infiltration of cardiac muscle and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination.

http://archive.today/2021.11.24-011123/https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712

Commentary from Dr. Vernon Coleman can be found here.

Categories
Publications

November 8, 2021 Summary Basis for Regulatory Action – Comirnaty – FDA

Introduction

BioNTech Manufacturing GmbH (in partnership with Pfizer Inc.) submitted a Biologics License Application (BLA) STN BL 125742 for licensure of COVID-19 Vaccine, mRNA. The proprietary name of the vaccine is COMIRNATY. COMIRNATY is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. The vaccine is administered intramuscularly (IM) as a series of two 30 μg doses (0.3 mL each) 3 weeks apart.

For commentary, see FDA report finds all-cause mortality higher among vaccinated – Israel Nation News.

http://archive.today/2021.10.11-032110/https://www.fda.gov/media/151733/download

Categories
Publications

Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial – BMJ

Revelations of poor practices at a contract research company helping to carry out Pfizer’s pivotal covid-19 vaccine trial raise questions about data integrity and regulatory oversight. Paul D Thacker reports

In autumn 2020 Pfizer’s chairman and chief executive, Albert Bourla, released an open letter to the billions of people around the world who were investing their hopes in a safe and effective covid-19 vaccine to end the pandemic. “As I’ve said before, we are operating at the speed of science,” Bourla wrote, explaining to the public when they could expect a Pfizer vaccine to be authorised in the United States.1

But, for researchers who were testing Pfizer’s vaccine at several sites in Texas during that autumn, speed may have come at the cost of data integrity and patient safety. A regional director who was employed at the research organisation Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial. Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding. After repeatedly notifying Ventavia of these problems, the regional director, Brook Jackson, emailed a complaint to the US Food and Drug Administration (FDA). Ventavia fired her later the same day. Jackson has provided The BMJ with dozens of internal company documents, photos, audio recordings, and emails.

Poor laboratory management
On its website Ventavia calls itself the largest privately owned clinical research company in Texas and lists many awards it has won for its contract work.2 But Jackson has told The BMJ that, during the two weeks she was employed at Ventavia in September 2020, she repeatedly informed her superiors of poor laboratory management, patient safety concerns, and data integrity issues. Jackson was a trained clinical trial auditor who previously held a director of operations position and came to Ventavia with more than 15 years’ experience in clinical research coordination and management. Exasperated that Ventavia was not dealing with the problems, Jackson documented several matters late one night, taking photos on her mobile phone. One photo, provided to The BMJ, showed needles discarded in a plastic biohazard bag instead of a sharps container box. Another showed vaccine packaging materials with trial participants’ identification numbers written on them left out in the open, potentially unblinding participants. Ventavia executives later questioned Jackson for taking the photos.

Early and inadvertent unblinding may have occurred on a far wider scale. According to the trial’s design, unblinded staff were responsible for preparing and administering the study drug (Pfizer’s vaccine or a placebo). This was to be done to preserve the blinding of trial participants and all other site staff, including the principal investigator. However, at Ventavia, Jackson told The BMJ that drug assignment confirmation printouts were being left in participants’ charts, accessible to blinded personnel. As a corrective action taken in September, two months into trial recruitment and with around 1000 participants already enrolled, quality assurance checklists were updated with instructions for staff to remove drug assignments from charts.

In a recording of a meeting in late September2020 between Jackson and two directors a Ventavia executive can be heard explaining that the company wasn’t able to quantify the types and number of errors they were finding when examining the trial paperwork for quality control. “In my mind, it’s something new every day,” a Ventavia executive says. “We know that it’s significant.”

Ventavia was not keeping up with data entry queries, shows an email sent by ICON, the contract research organisation with which Pfizer partnered on the trial. ICON reminded Ventavia in a September 2021 email: “The expectation for this study is that all queries are addressed within 24hrs.” ICON then highlighted over 100 outstanding queries older than three days in yellow. Examples included two individuals for which “Subject has reported with Severe symptoms/reactions … Per protocol, subjects experiencing Grade 3 local reactions should be contacted. Please confirm if an UNPLANNED CONTACT was made and update the corresponding form as appropriate.” According to the trial protocol a telephone contact should have occurred “to ascertain further details and determine whether a site visit is clinically indicated.”

Worries over FDA inspection
Documents show that problems had been going on for weeks. In a list of “action items” circulated among Ventavia leaders in early August 2020, shortly after the trial began and before Jackson’s hiring, a Ventavia executive identified three site staff members with whom to “Go over e-diary issue/falsifying data, etc.” One of them was “verbally counseled for changing data and not noting late entry,” a note indicates. At several points during the late September meeting Jackson and the Ventavia executives discussed the possibility of the FDA showing up for an inspection (box 1). “We’re going to get some kind of letter of information at least, when the FDA gets here . . . know it,” an executive stated.

Box 1
A history of lax oversight
When it comes to the FDA and clinical trials, Elizabeth Woeckner, president of Citizens for Responsible Care and Research Incorporated (CIRCARE),3 says the agency’s oversight capacity is severely under-resourced. If the FDA receives a complaint about a clinical trial, she says the agency rarely has the staff available to show up and inspect. And sometimes oversight occurs too late.

In one example CIRCARE and the US consumer advocacy organisation Public Citizen, along with dozens of public health experts, filed a detailed complaint in July 2018 with the FDA about a clinical trial that failed to comply with regulations for the protection of human participants.4 Nine months later, in April 2019, an FDA investigator inspected the clinical site. In May this year the FDA sent the triallist a warning letter that substantiated many of the claims in the complaints. It said, “[I]t appears that you did not adhere to the applicable statutory requirements and FDA regulations governing the conduct of clinical investigations and the protection of human subjects.”5

“There’s just a complete lack of oversight of contract research organisations and independent clinical research facilities,” says Jill Fisher, professor of social medicine at the University of North Carolina School of Medicine and author of Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials.

Ventavia and the FDA
A former Ventavia employee told The BMJ that the company was nervous and expecting a federal audit of its Pfizer vaccine trial.

“People working in clinical research are terrified of FDA audits,” Jill Fisher told The BMJ, but added that the agency rarely does anything other than inspect paperwork, usually months after a trial has ended. “I don’t know why they’re so afraid of them,” she said. But she said she was surprised that the agency failed to inspect Ventavia after an employee had filed a complaint. “You would think if there’s a specific and credible complaint that they would have to investigate that,” Fisher said.

In 2007 the Department of Health and Human Services’ Office of the Inspector General released a report on FDA’s oversight of clinical trials conducted between 2000 and 2005. The report found that the FDA inspected only 1% of clinical trial sites.6 Inspections carried out by the FDA’s vaccines and biologics branch have been decreasing in recent years, with just 50 conducted in the 2020 fiscal year.7


The next morning, 25 September 2020, Jackson called the FDA to warn about unsound practices in Pfizer’s clinical trial at Ventavia. She then reported her concerns in an email to the agency. In the afternoon Ventavia fired Jackson—deemed “not a good fit,” according to her separation letter.

Jackson told The BMJ it was the first time she had been fired in her 20 year career in research.

Concerns raised
In her 25 September email to the FDA Jackson wrote that Ventavia had enrolled more than 1000 participants at three sites. The full trial (registered under NCT04368728) enrolled around 44 000 participants across 153 sites that included numerous commercial companies and academic centres. She then listed a dozen concerns she had witnessed, including:
-Participants placed in a hallway after injection and not being monitored by clinical staff
-Lack of timely follow-up of patients who experienced adverse events
-Protocol deviations not being reported
-Vaccines not being stored at proper temperatures
-Mislabelled laboratory specimens, and
-Targeting of Ventavia staff for reporting these types of problems.
Within hours Jackson received an email from the FDA thanking her for her concerns and notifying her that the FDA could not comment on any investigation that might result. A few days later Jackson received a call from an FDA inspector to discuss her report but was told that no further information could be provided. She heard nothing further in relation to her report.

In Pfizer’s briefing document submitted to an FDA advisory committee meeting held on 10 December 2020 to discuss Pfizer’s application for emergency use authorisation of its covid-19 vaccine, the company made no mention of problems at the Ventavia site. The next day the FDA issued the authorisation of the vaccine.8

In August this year, after the full approval of Pfizer’s vaccine, the FDA published a summary of its inspections of the company’s pivotal trial. Nine of the trial’s 153 sites were inspected. Ventavia’s sites were not listed among the nine, and no inspections of sites where adults were recruited took place in the eight months after the December 2020 emergency authorisation. The FDA’s inspection officer noted: “The data integrity and verification portion of the BIMO [bioresearch monitoring] inspections were limited because the study was ongoing, and the data required for verification and comparison were not yet available to the IND [investigational new drug].”

Other employees’ accounts
In recent months Jackson has reconnected with several former Ventavia employees who all left or were fired from the company. One of them was one of the officials who had taken part in the late September meeting. In a text message sent in June the former official apologised, saying that “everything that you complained about was spot on.”

Two former Ventavia employees spoke to The BMJ anonymously for fear of reprisal and loss of job prospects in the tightly knit research community. Both confirmed broad aspects of Jackson’s complaint. One said that she had worked on over four dozen clinical trials in her career, including many large trials, but had never experienced such a “helter skelter” work environment as with Ventavia on Pfizer’s trial.

“I’ve never had to do what they were asking me to do, ever,” she told The BMJ. “It just seemed like something a little different from normal—the things that were allowed and expected.”

She added that during her time at Ventavia the company expected a federal audit but that this never came.

After Jackson left the company problems persisted at Ventavia, this employee said. In several cases Ventavia lacked enough employees to swab all trial participants who reported covid-like symptoms, to test for infection. Laboratory confirmed symptomatic covid-19 was the trial’s primary endpoint, the employee noted. (An FDA review memorandum released in August this year states that across the full trial swabs were not taken from 477 people with suspected cases of symptomatic covid-19.)

“I don’t think it was good clean data,” the employee said of the data Ventavia generated for the Pfizer trial. “It’s a crazy mess.”

A second employee also described an environment at Ventavia unlike any she had experienced in her 20 years doing research. She told The BMJ that, shortly after Ventavia fired Jackson, Pfizer was notified of problems at Ventavia with the vaccine trial and that an audit took place.

Since Jackson reported problems with Ventavia to the FDA in September 2020, Pfizer has hired Ventavia as a research subcontractor on four other vaccine clinical trials (covid-19 vaccine in children and young adults, pregnant women, and a booster dose, as well an RSV vaccine trial; NCT04816643, NCT04754594, NCT04955626, NCT05035212). The advisory committee for the Centers for Disease Control and Prevention is set to discuss the covid-19 paediatric vaccine trial on 2 November.

Footnotes
Provenance and peer review: commissioned; externally peer reviewed.

Competing interests: PDT has been doubly vaccinated with Pfizer’s vaccine.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

References
* Bourla A. An open letter from Pfizer chairman and CEO Albert Bourla. Pfizer. https://www.pfizer.com/news/hot-topics/an_open_letter_from_pfizer_chairman_and_ceo_albert_bourla.
* Ventavia. A leading force in clinical research trials. https://www.ventaviaresearch.com/company.
* Citizens for Responsible Care and Research Incorporated (CIRCARE). http://www.circare.org/corp.htm.
* Public Citizen. Letter to Scott Gottlieb and Jerry Menikoff. Jul 2018. https://www.citizen.org/wp-content/uploads/2442.pdf.
↵Food and Drug Administration. Letter to John B Cole MD. MARCS-CMS 611902. May 2021. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jon-b-cole-md-611902-05052021.
* Department of Health and Human Services Office of Inspector General. The Food and Drug Administration’s oversight of clinical trials. Sep 2007. https://www.oig.hhs.gov/oei/reports/oei-01-06-00160.pdf.
* Food and Drug Administration. Bioresearch monitoring. https://www.fda.gov/media/145858/download.
* FDA takes key action in fight against covid-19 by issuing emergency use authorization for first covid-19 vaccine. Dec 2020. https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19.

Original article: https://www.bmj.com/content/375/bmj.n2635

Archive mirrors:

Categories
Publications

Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination JAMA

In this population-based cohort study, we found that the CVST incidence rate 15 days after Ad26.COV2.S vaccination was significantly higher than the prepandemic rate. However, the higher rate of this rare adverse effect must be considered in the context of the effectiveness of the vaccine in preventing COVID-19 (absolute reduction of severe or critical COVID-19 of 940 per 100 000 PY).

http://archive.today/2021.11.02-171706/https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785610

Categories
Publications

Cognitive Warfare – The Innovation Hub

Published November 2020

As global conflicts take on increasingly asymmetric and “grey” forms, the ability to manipulate the human mind employing neurocognitive science techniques and tools is constantly and quickly increasing. This complements the more traditional techniques of manipulation through information technology and information warfare, making the human increasingly targeted in the cognitive warfare. 

Any user of modern information technologies is a potential target. It targets the whole of a nation’s human capital.

Cognitive Warfare, June-November 2020, p. 6

Original: https://www.innovationhub-act.org/sites/default/files/2021-01/20210122_CW%20Final.pdf

Archive: http://archive.today/2021.10.21-043819/https://www.innovationhub-act.org/sites/default/files/2021-01/20210122_CW%20Final.pdf

Categories
Publications

Net Zero: principles for successful behaviour change initiatives – Department for Business, Energy & Industrial Strategy

“For instance, even with public criticism being high, many still perceived government approval as the yardstick for safe behaviour during COVID-19 ‘we’re allowed to do this now [so must be safe]…’. This reveals, for many, a deep set reverence for legitimate government authority, regardless of one’s personal political views.”

Net Zero: principles for successful behaviour change initiatives, p.24

This research looks at UK and OECD government-led behaviour change initiatives over the last 70 years. It identifies 9 principles that can be applied to encourage the behaviour change needed to achieve Net Zero.

The research was carried out by the Behavioural Insights Team (BIT). It was commissioned by the Department for Business, Energy and Industrial Strategy (BEIS).

https://www.gov.uk/government/publications/net-zero-principles-for-successful-behaviour-change-initiatives

This document has been removed from the gov.uk website. Archives can be found here:

Categories
Publications

Recent deaths in young people in England and Wales – HART

The mortality data for England and Wales from ONS from 1 May 2021 until 17 September 2021 shows a significant excess, particularly in the 15-19 year age group. Depending on the baseline chosen, the excess for 15-19 year olds is between 16% and 47% above expected levels (see table 1 and 2). COVID-19 deaths were too small in number to account for the excess. A disproportionate number of these excess deaths were in males. A certain amount of variation by random chance would be expected but an increase of this proportion is large enough not to be dismissed without further investigation.

…Mortality has risen in younger age groups since 1st May 2021. The increase in the 15-19 year old age group is particularly noticeable, especially as deaths in this age group are uncommon. The excess deaths have a marked male predominance. An increase in ambulance call outs for patients who have had a cardiac arrest or are unconscious showed a coincidental noticeable rise from May 2021. The period also coincides with the rollout of vaccination. Finally, ONS have reported on a striking rise in age adjusted mortality rates in those with only one dose that accelerated in May 2021 to levels far exceeding those in the unvaccinated.

Table 1 and Table 2: Mortality from 1st May 2021 to 17th September by age group. Table 1 uses a 2020 baseline and table 2 uses a mean from 2015-2019.
Figure 7 Age adjusted non-COVID mortality rates by vaccination status as published by ONS on 13th September 

https://www.hartgroup.org/recent-deaths-in-young-people-in-england-and-wales/

Categories
Publications

Iceland halts Moderna jabs over heart-inflammation fears – Medical Xpress

Iceland on Friday suspended the Moderna anti-COVID vaccine, citing the slight increased risks of cardiac inflammation, going further than its Nordic neighbours which simply limited use of the jabs.

…This decision owed to “the increased incidence of myocarditis and pericarditis after vaccination with the Moderna vaccine, as well as with vaccination using Pfizer/BioNTech,” the chief epidemiologist said in a statement.

https://medicalxpress.com/news/2021-10-iceland-halts-moderna-jabs-heart-inflammation.html

Categories
Publications

Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021 – Eurosurveillance

This nosocomial outbreak exemplifies the high transmissibility of the SARS-CoV-2 Delta variant among twice vaccinated and masked individuals. This suggests some waning of immunity, albeit still providing protection for individuals without comorbidities. However, a third vaccine dose may be needed, particularly in individuals with risk factors for severe COVID-19. Appropriate use of masks, especially in high-risk settings is advised.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.39.2100822#html_fulltext